NCT03493919View on ClinicalTrials.gov

A Sourcing Study to Collect Human Blood Samples From Healthy Adults

PHASE4CompletedINTERVENTIONAL
Enrollment

1,021

Participants

Timeline

Start Date

March 8, 2018

Primary Completion Date

May 27, 2022

Study Completion Date

May 27, 2022

Conditions
Meningitis, Meningococcal
Interventions
BIOLOGICAL

rMenB+OMV NZ vaccine

Two doses of rMenB+OMV NZ vaccine were administered intramuscularly at Day 1 and Day 61.

BIOLOGICAL

Meningococcal Groups A, C, W and Y Conjugate Vaccine (MenACWY)

One dose of MenACWY vaccine were administered intramuscularly at Day 1.

Trial Locations (6)

2010

GSK Investigational Site, Sydney

3004

GSK Investigational Site, Melbourne

3220

GSK Investigational Site, Geelong

5000

GSK Investigational Site, Adelaide

6163

GSK Investigational Site, Spearwood

97070

GSK Investigational Site, Würzburg

Sponsors

Lead Sponsor

GlaxoSmithKline
All Listed Sponsors
lead

GlaxoSmithKline

INDUSTRY